Duration of Benefit in Patients With Autoimmune Pulmonary Alveolar Proteinosis After Inhaled Granulocyte-Macrophage Colony-Stimulating Factor Therapy.

The article presents a study which examines the duration of benefits from inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy in patients with autoimmune pulmonary alveolar proteinosis (aPAP). It is inferred that the study aims to clarify the risk factors for aPAP recurrence following the inhalation of GM-CSF. According to the study, vital capacity might be a prognostic factor for disease recurrence.